Cargando…
Single nucleotide polymorphisms in C-reactive protein (CRP) predict response to adjunctive celecoxib treatment of resistant bipolar depression
BACKGROUND: Affective illness has been associated with a proinflammatory state, and it is generally accepted that the immune system plays a key role in the pathophysiology of mood disorders. Since inflammatory biomarkers are elevated in bipolar disorder, anti-inflammatory combination therapies may e...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172701/ https://www.ncbi.nlm.nih.gov/pubmed/37181328 http://dx.doi.org/10.1016/j.bbih.2023.100625 |
_version_ | 1785039667970703360 |
---|---|
author | Halaris, Angelos Hain, Daniel Law, Rebecca Brown, Lisa Lewis, David Filip, Maria |
author_facet | Halaris, Angelos Hain, Daniel Law, Rebecca Brown, Lisa Lewis, David Filip, Maria |
author_sort | Halaris, Angelos |
collection | PubMed |
description | BACKGROUND: Affective illness has been associated with a proinflammatory state, and it is generally accepted that the immune system plays a key role in the pathophysiology of mood disorders. Since inflammatory biomarkers are elevated in bipolar disorder, anti-inflammatory combination therapies may enhance response and reverse treatment resistance. PURPOSE: In the present study we investigated the possible impact of single nucleotide polymorphisms (SNPs) within the CRP gene on CRP blood levels, treatment response and level-of-stress perception in our cohort of treatment-resistant bipolar-depressed patients receiving escitalopram and celecoxib, or escitalopram and placebo, as previously reported (Halaris et al., 2020). METHODS: Study design, clinical findings, and CRP blood levels have been reported previously (Halaris et al., 2020; Edberg et al., 2018). In this follow-up study we extracted DNA from blood cells collected at baseline. Genome-wide genotyping was performed for all subjects using the Infinium Multi-Ethnic Global-8 v1.0 Kit. Based on reports in the literature indicating possible associations with psychiatric conditions, ten previously reported CRP gene polymorphisms were evaluated in a preliminary analysis. We focused on rs3093059 and rs3093077 were in complete LD. Carriers were defined as those possessing at least one C allele for rs3093059, or at least one G allele for rs3093077. Additionally, we determined blood levels of the medications administered. RESULTS: Non-carriers of rs3093059 and rs3093077 had significantly lower baseline CRP blood levels than carriers (p = 0.03). Increased rates of HAM-D17 response (p = 0.21) and remission (p = 0.13) and lower PSS-14 scores (p = 0.13) were observed in non-carriers among subjects receiving celecoxib but they did not reach statistical significance. When examining all subjects, nominally significant associations between carrier-status and remission (p = 0.04) and PSS-14 scores (p = 0.04) were observed after correcting for treatment arm. Non-carriers receiving celecoxib had the highest rates of response and remission, and the lowest stress scores. CONCLUSIONS: Carriers of the CRP SNPs may have higher baseline CRP levels, although non-carriers appear to benefit more from celecoxib co-therapy. Determination of the carrier status in conjunction with pretreatment blood CRP level measurement may contribute to personalized psychiatric practice, but replication of the present findings is needed. |
format | Online Article Text |
id | pubmed-10172701 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-101727012023-05-12 Single nucleotide polymorphisms in C-reactive protein (CRP) predict response to adjunctive celecoxib treatment of resistant bipolar depression Halaris, Angelos Hain, Daniel Law, Rebecca Brown, Lisa Lewis, David Filip, Maria Brain Behav Immun Health Full Length Article BACKGROUND: Affective illness has been associated with a proinflammatory state, and it is generally accepted that the immune system plays a key role in the pathophysiology of mood disorders. Since inflammatory biomarkers are elevated in bipolar disorder, anti-inflammatory combination therapies may enhance response and reverse treatment resistance. PURPOSE: In the present study we investigated the possible impact of single nucleotide polymorphisms (SNPs) within the CRP gene on CRP blood levels, treatment response and level-of-stress perception in our cohort of treatment-resistant bipolar-depressed patients receiving escitalopram and celecoxib, or escitalopram and placebo, as previously reported (Halaris et al., 2020). METHODS: Study design, clinical findings, and CRP blood levels have been reported previously (Halaris et al., 2020; Edberg et al., 2018). In this follow-up study we extracted DNA from blood cells collected at baseline. Genome-wide genotyping was performed for all subjects using the Infinium Multi-Ethnic Global-8 v1.0 Kit. Based on reports in the literature indicating possible associations with psychiatric conditions, ten previously reported CRP gene polymorphisms were evaluated in a preliminary analysis. We focused on rs3093059 and rs3093077 were in complete LD. Carriers were defined as those possessing at least one C allele for rs3093059, or at least one G allele for rs3093077. Additionally, we determined blood levels of the medications administered. RESULTS: Non-carriers of rs3093059 and rs3093077 had significantly lower baseline CRP blood levels than carriers (p = 0.03). Increased rates of HAM-D17 response (p = 0.21) and remission (p = 0.13) and lower PSS-14 scores (p = 0.13) were observed in non-carriers among subjects receiving celecoxib but they did not reach statistical significance. When examining all subjects, nominally significant associations between carrier-status and remission (p = 0.04) and PSS-14 scores (p = 0.04) were observed after correcting for treatment arm. Non-carriers receiving celecoxib had the highest rates of response and remission, and the lowest stress scores. CONCLUSIONS: Carriers of the CRP SNPs may have higher baseline CRP levels, although non-carriers appear to benefit more from celecoxib co-therapy. Determination of the carrier status in conjunction with pretreatment blood CRP level measurement may contribute to personalized psychiatric practice, but replication of the present findings is needed. Elsevier 2023-04-20 /pmc/articles/PMC10172701/ /pubmed/37181328 http://dx.doi.org/10.1016/j.bbih.2023.100625 Text en © 2023 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Full Length Article Halaris, Angelos Hain, Daniel Law, Rebecca Brown, Lisa Lewis, David Filip, Maria Single nucleotide polymorphisms in C-reactive protein (CRP) predict response to adjunctive celecoxib treatment of resistant bipolar depression |
title | Single nucleotide polymorphisms in C-reactive protein (CRP) predict response to adjunctive celecoxib treatment of resistant bipolar depression |
title_full | Single nucleotide polymorphisms in C-reactive protein (CRP) predict response to adjunctive celecoxib treatment of resistant bipolar depression |
title_fullStr | Single nucleotide polymorphisms in C-reactive protein (CRP) predict response to adjunctive celecoxib treatment of resistant bipolar depression |
title_full_unstemmed | Single nucleotide polymorphisms in C-reactive protein (CRP) predict response to adjunctive celecoxib treatment of resistant bipolar depression |
title_short | Single nucleotide polymorphisms in C-reactive protein (CRP) predict response to adjunctive celecoxib treatment of resistant bipolar depression |
title_sort | single nucleotide polymorphisms in c-reactive protein (crp) predict response to adjunctive celecoxib treatment of resistant bipolar depression |
topic | Full Length Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10172701/ https://www.ncbi.nlm.nih.gov/pubmed/37181328 http://dx.doi.org/10.1016/j.bbih.2023.100625 |
work_keys_str_mv | AT halarisangelos singlenucleotidepolymorphismsincreactiveproteincrppredictresponsetoadjunctivecelecoxibtreatmentofresistantbipolardepression AT haindaniel singlenucleotidepolymorphismsincreactiveproteincrppredictresponsetoadjunctivecelecoxibtreatmentofresistantbipolardepression AT lawrebecca singlenucleotidepolymorphismsincreactiveproteincrppredictresponsetoadjunctivecelecoxibtreatmentofresistantbipolardepression AT brownlisa singlenucleotidepolymorphismsincreactiveproteincrppredictresponsetoadjunctivecelecoxibtreatmentofresistantbipolardepression AT lewisdavid singlenucleotidepolymorphismsincreactiveproteincrppredictresponsetoadjunctivecelecoxibtreatmentofresistantbipolardepression AT filipmaria singlenucleotidepolymorphismsincreactiveproteincrppredictresponsetoadjunctivecelecoxibtreatmentofresistantbipolardepression |